191 related articles for article (PubMed ID: 34259900)
21. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.
Singer K; Kastenberger M; Gottfried E; Hammerschmied CG; Büttner M; Aigner M; Seliger B; Walter B; Schlösser H; Hartmann A; Andreesen R; Mackensen A; Kreutz M
Int J Cancer; 2011 May; 128(9):2085-95. PubMed ID: 20607826
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of single-cell RNA-seq and bulk RNA-seq revealed the heterogeneity and convergence of the immune microenvironment in renal cell carcinoma.
Lv S; Tao L; Liao H; Huang Z; Lu Y
Funct Integr Genomics; 2023 Jun; 23(2):193. PubMed ID: 37264263
[TBL] [Abstract][Full Text] [Related]
23. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
24. Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy.
Shen YC; Yeh CP; Jeng YM; Hsu C; Hsu CH; Lin ZZ; Shao YY; Lu LC; Liu TH; Chen CH; Cheng AL
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680292
[TBL] [Abstract][Full Text] [Related]
25. CD39
Tallón de Lara P; Castañón H; Vermeer M; Núñez N; Silina K; Sobottka B; Urdinez J; Cecconi V; Yagita H; Movahedian Attar F; Hiltbrunner S; Glarner I; Moch H; Tugues S; Becher B; van den Broek M
Nat Commun; 2021 Feb; 12(1):769. PubMed ID: 33536445
[TBL] [Abstract][Full Text] [Related]
26. Tim-3 Expression on Tumor-Infiltrating PD-1
Granier C; Dariane C; Combe P; Verkarre V; Urien S; Badoual C; Roussel H; Mandavit M; Ravel P; Sibony M; Biard L; Radulescu C; Vinatier E; Benhamouda N; Peyromaure M; Oudard S; Méjean A; Timsit MO; Gey A; Tartour E
Cancer Res; 2017 Mar; 77(5):1075-1082. PubMed ID: 27872087
[TBL] [Abstract][Full Text] [Related]
27. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
[TBL] [Abstract][Full Text] [Related]
29. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
J Immunother; 2015 Sep; 38(7):285-91. PubMed ID: 26261892
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
Meng J; Tan JYT; Joseph CR; Ye J; Lim JCT; Goh D; Xue Y; Lim X; Koh VCY; Wee F; Tay TKY; Chan JY; Ng CCY; Iqbal J; Lau MC; Lim HE; Toh HC; Teh BT; Dent RA; Tan PH; Yeong JPS
Lab Invest; 2024 Mar; 104(3):100303. PubMed ID: 38103870
[TBL] [Abstract][Full Text] [Related]
31. Identification of clinically relevant subsets CD39
Zhang QW; Zhu MX; Liu WF; Rui WW; Chen Y; Ding XY; Jiang YS; Wu ZY; Liu BB
Transl Oncol; 2024 Jun; 44():101954. PubMed ID: 38608405
[TBL] [Abstract][Full Text] [Related]
32. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
[TBL] [Abstract][Full Text] [Related]
33. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
34. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
Gigante M; Pontrelli P; Herr W; Gigante M; D'Avenia M; Zaza G; Cavalcanti E; Accetturo M; Lucarelli G; Carrieri G; Battaglia M; Storkus WJ; Gesualdo L; Ranieri E
J Transl Med; 2016 Apr; 14():84. PubMed ID: 27063186
[TBL] [Abstract][Full Text] [Related]
35. The ectonucleotidase CD39 identifies tumor-reactive CD8
Chow A; Uddin FZ; Liu M; Dobrin A; Nabet BY; Mangarin L; Lavin Y; Rizvi H; Tischfield SE; Quintanal-Villalonga A; Chan JM; Shah N; Allaj V; Manoj P; Mattar M; Meneses M; Landau R; Ward M; Kulick A; Kwong C; Wierzbicki M; Yavner J; Egger J; Chavan SS; Farillas A; Holland A; Sridhar H; Ciampricotti M; Hirschhorn D; Guan X; Richards AL; Heller G; Mansilla-Soto J; Sadelain M; Klebanoff CA; Hellmann MD; Sen T; de Stanchina E; Wolchok JD; Merghoub T; Rudin CM
Immunity; 2023 Jan; 56(1):93-106.e6. PubMed ID: 36574773
[TBL] [Abstract][Full Text] [Related]
36. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
37. Abundant CD8+ tumor infiltrating lymphocytes and beta-2-microglobulin are associated with better outcome and response to interleukin-2 therapy in advanced stage clear cell renal cell carcinoma.
Davis D; Tretiakova MS; Kizzar C; Woltjer R; Krajbich V; Tykodi SS; Lanciault C; Andeen NK
Ann Diagn Pathol; 2020 Aug; 47():151537. PubMed ID: 32454441
[TBL] [Abstract][Full Text] [Related]
38. Obesity diminishes response to PD-1-based immunotherapies in renal cancer.
Boi SK; Orlandella RM; Gibson JT; Turbitt WJ; Wald G; Thomas L; Buchta Rosean C; Norris KE; Bing M; Bertrand L; Gross BP; Makkouk A; Starenki D; Farag KI; Sorge RE; Brown JA; Gordetsky J; Yasin H; Garje R; Nandagopal L; Weiner GJ; Lubaroff DM; Arend RC; Li P; Zakharia Y; Yang E; Salem AK; Nepple K; Marquez-Lago TT; Norian LA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427691
[TBL] [Abstract][Full Text] [Related]
39. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
Izawa M; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Kakimi K; Imamura T; Matsumoto K; Oya M
Lab Invest; 2023 Apr; 103(4):100040. PubMed ID: 36870289
[TBL] [Abstract][Full Text] [Related]
40. Establishment of a Seven-Gene Signature Associated with CD8
Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
